219599-99-2

Basic information

• Product Name: 2-tert-Butyl-4-(piperazin-1-yl)-6-trifluoromethyl-pyrimidine
• Synonyms: 2-tert-Butyl-4-(piperazin-1-yl)-6-trifluoromethyl-pyrimidine;2-t-Butyl-4-(1-piperazinyl)-6-trifluoroMethylpyriMidine
• CAS NO: 219599-99-2
• Molecular Formula: C₁₃H₁₉F₃N₄
• Molecular Weight: 288.31
• Product Categories: pharmacetical
• Mol File: 219599-99-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 363.3°Cat760mmHg
• Flash Point: 173.5°C
• Appearance: /
• Density: 1.179g/cm³
• Vapor Pressure: 1.82E-05mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-tert-Butyl-4-(piperazin-1-yl)-6-trifluoromethyl-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tert-Butyl-4-(piperazin-1-yl)-6-trifluoromethyl-pyrimidine(219599-99-2)
• EPA Substance Registry System: 2-tert-Butyl-4-(piperazin-1-yl)-6-trifluoromethyl-pyrimidine(219599-99-2)

Safety Data

• Hazardous Substances Data: 219599-99-2(Hazardous Substances Data)

Usage

Uses

1-[2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl]piperazine is an intermediate in the synthesis of ABT 925 Fumerate (A112600) is a dopamine D3 receptor antagonist that is used in the treatment of acute schizophrenia.

InChI:InChI=1/C13H19F3N4/c1-12(2,3)11-18-9(13(14,15)16)8-10(19-11)20-6-4-17-5-7-20/h8,17H,4-7H2,1-3H3

Upstream product

• 110-85-0 piperazine 
• 1722-12-9 2-chloropyrimidine 
• 193611-28-8 2-t-butyl-4-chloro-6-trifluoromethylpyrimidine 

Downstream Products

• 1596371-66-2 N-(4-(4-(2-(tert-butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-1-phenylpiperidine-4-carboxamide 
• 1596371-68-4 1-benzyl-N-(4-(4-(2-(tert-butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)piperidine-4-carboxamide 

Relevant articles and documents

Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: Insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity

Antagonist and partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders. However, development of druglike lead compounds with selectivity for the D3 receptor has been challenging because of the high sequence homology between the D3R and the dopamine D2 receptor (D2R). In this effort, we synthesized a series of acylaminobutylpiperazines incorporating aza-aromatic units and evaluated their binding and functional activities at the D3 and D2 receptors. Docking studies and results from evaluations against a set of chimeric and mutant receptors suggest that interactions at the extracellular end of TM7 contribute to the D3R versus D2R selectivity of these ligands. Molecular insights from this study could potentially enable rational design of potent and selective D3R ligands.

2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate

The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.

2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE

The fumaric acid salt of 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol is useful for treating disorders which respond to dopamine D3 ligands. It has higher stability at low pH and is therefore particularly suitable for oral administration in pharmaceutical compositions comprising this salt.